Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
Tóm tắt
To estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (LABA) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis with a history of frequent exacerbations from the UK payer perspective. A Markov model was developed to predict the lifetime cost and outcomes [exacerbations rates, life expectancy, and quality-adjusted life years (QALY)] in patients treated with roflumilast, which showed a reduction in the exacerbation rates and lung function improvement in a pooled analysis from two clinical trials, M2-124 and M2-125. Sensitivity analyses were conducted to explore the impact of uncertainties on the cost-effectiveness. The addition of roflumilast to concomitant LABA reduced the number of exacerbations from 15.6 to 12.7 [2.9 (95 % CI 0.88–4.92) exacerbations avoided] and increased QALYs from 5.45 to 5.61 [0.16 (95 % CI 0.02–0.31) QALYs gained], at an incremental cost of £3,197 (95 % CI £2,135–£4,253). Cost in LABA alone and LABA + roflumilast were £16,161 and £19,358 respectively. The incremental cost-effectiveness ratios in the base case were £19,505 (95 % CI £364–£38,646) per quality-adjusted life-year gained and 18,219 (95 % CI £12,697–£49,135) per life-year gained. Sensitivity analyses suggest that among the main determinants of cost-effectiveness are the reduction of exacerbations and the case fatality rate due to hospital-treated exacerbations. Probabilistic sensitivity analysis suggests that the probability of roflumilast being cost-effective is 82 % at willingness-to-pay £30,000 per QALY. The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting.
Tài liệu tham khảo
Halbert, R.J., Natoli, J.L., Gano, A., Badamgarav, E., Buist, A.S., Mannino, D.M.: Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28(3), 523–532 (2006)
Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011)
Jones, P.W.: Activity limitation and quality of life in COPD. COPD 4(3), 273–278 (2007)
Roche, N.: Activity limitation: a major consequence of dyspnoea in COPD. Eur. Respir.Rev. 18(112), 54–57 (2009)
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Health and Clinical Excellence (2010)
Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M., Martinez, F.J.: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685–694 (2009)
FitzGerald, J.M., Haddon, J.M., Bradly-Kennedy, C., Kuramoto, L., Ford, G.T.: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 14(3), 145–152 (2007)
Oostenbrink, J.B., Rutten-van Mölken, M.P.: Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98(9), 883–891 (2004)
Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A.: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847–852 (2002)
Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 64(10), 894–900 (2009)
Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax 65(6), 499–504 (2010)
Oostenbrink, J.B., Rutten-van Mölken, M.P., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32–46 (2005)
Rutten-van Mölken, M.P., Lee, T.A.: Economic modeling in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3(7), 630–634 (2006)
European Public Assessment Report (EPAR) for Daxas. Product information. 28/03/2011 Daxas -EMEA/H/C/001179-IB/0002. 20-7-2010 (2010)
Bateman, E.D., Rabe, K.F., Calverley, P.M., Goehring, U.M., Brose, M., Bredenbröker, D., Fabbri, L.M.: Roflumilast with long-acting ß2 agonists for COPD: influence of exacerbation history. Eur. Respir. J. 38(3), 553–560 (2011)
Selected subgroup analyses based on data from Studies M2-124 and M2-125 in subpopulation of LABA-treated patients and subpopulation of LABA-treated patients with at least two COPD exacerbations in the previous year. 16-7-2010. Nycomed International Management GmbH (2010)
Crapo, R.O., Morris, A.H., Gardner, R.M.: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123(6), 659–664 (1981)
Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C., Buist, A.S.: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381–390 (2000)
Statistical report. Effect of roflumilast on exacerbation rates in based on data from studies M2-124 and M2-125 in subpopulation of LABA-treated patients. Nycomed International Management GmbH (2009)
Report of the 2008 National COPD Audit: The Royal College of Physicians and the British Thoracic Society (2008)
Hoogendoorn, M., Hoogenveen, R.T., Rutten-van Mölken, M.P., Vestbo, J., Feenstra, T.L.: Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur. Respir. J. 37(3), 508–515 (2011)
Ekberg-Aronsson, M., Pehrsson, K., Nilsson, J.A., Nilsson, P.M., Lofdahl, C.G.: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir. Res. 6(1), 98 (2005). doi:10.1186/1465-9921-6-98
Rutten-van Mölken, M.P., Hoogendoorn, M., Lamers, L.M.: Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 27(6), 465–477 (2009)
British National Formulary. British Medical Association and Royal Pharmaceutical Society, London (2010)
NHS reference costs 2009–2010. 13-1-2011. UK Department of Health (2011)
Claxton, K., Sculpher, M., McCabe, C., Briggs, A., Akehurst, R., Buxton, M., Brazier, J., O’Hagan, T.: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339–347 (2005)
Borg, S., Ericsson, A., Wedzicha, J., Gulsvik, A., Lundbäck, B., Donaldson, G.C., Sullivan, S.D.: A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7(2), 153–167 (2004)
Earnshaw, S.R., Wilson, M.R., Dalal, A.A., Chambers, M.G., Jhingran, P., Stanford, R., Mapel, D.W.: Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir. Med. 103(1), 12–21 (2009)
Oba, Y.: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am. J. Manag. Care 15(4), 226–232 (2009)
Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23(6), 619–637 (2005)
Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., TORCH investigators.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775–789 (2007)
Hanania, N.A.: The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm. Pharmacol. Ther. 21(3), 540–550 (2008)
Tashkin, D., Celli, B., Kesten, S., Lystig, T., Decramer, M.: Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir. Med. 104(10), 1495–1504 (2010)
Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., UPLIFT Study Investigators.: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 359(15), 1543–1554 (2008)
Martinez, F.J., Rabe, K.F., Goehring, U.M., Lakkis, H., Rowe, P., Palm, U.: Roflumilast prolongs time to first and subsequent exacerbations in patients with severe to very severe COPD. In: American Thoracic Society International Conference. ATS-2011. Denver, Colorado, USA. 13-5-2011 (2011)
Mills, E.J., Druyts. E., Ghement, I., Puhan M.A.: Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin. Epidemiol. 3, 107–129 (2011)
Hertel, N., Kotchie, R.W., Samyshkin, Y., Radford, M., Humphreys, S., Jameson, K.: Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 183–199 (2012)
Rabe, K.F.: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 163(1), 53–67 (2011)
Personal Social Services Research Unit, UK. Unit Costs of Health and Social Care 2009. http://www.pssru.ac.uk/archive/pdf/uc/uc2009/uc2009.pdf (2009)